Experienced in Frontotemporal Dementia

Ming-jang J. Chiu

No. 7 Chung Shan South Road, 100, 
TPQ, TW 
Experienced in Frontotemporal Dementia
No. 7 Chung Shan South Road, 100, 
TPQ, TW 
OverviewLocationsClinical Research

Overview

Ming-jang Chiu practices in Taiwan. Chiu is rated as an Experienced expert by MediFind in the treatment of Frontotemporal Dementia. Their top areas of expertise are Dementia, Alzheimer's Disease, Developmental Dysphasia Familial, Gastrostomy, and Stent Placement.

Their clinical research consists of co-authoring 103 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 7 articles in the study of Frontotemporal Dementia.

Locations

No. 7 Chung Shan South Road, 100, TPQ, Taiwan
Other Locations
No. 1, Changde Street, TPQ 10048, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An Extension Study of a Phase IIa Study in Patients With Mild Alzheimer's Disease to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311)
An Extension Study of a Phase IIa Study in Patients With Mild Alzheimer's Disease to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311)
Enrollment Status: Terminated
Publish Date: January 26, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, 3-arm Parallel-group, Multicenter, Phase IIa Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311) in Patients With Mild Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, 3-arm Parallel-group, Multicenter, Phase IIa Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311) in Patients With Mild Alzheimer's Disease
Enrollment Status: Completed
Publish Date: March 17, 2020
Intervention Type: Drug, Biological
Study Phase: Phase 2
View 1 Less Clinical Trial

103 Total Publications

Survival After the Diagnosis of Mild-to-Moderate Alzheimer's Disease Dementia: A 15-Year National Cohort Study in Taiwan.
Survival After the Diagnosis of Mild-to-Moderate Alzheimer's Disease Dementia: A 15-Year National Cohort Study in Taiwan.
Journal: International journal of geriatric psychiatry
Published: February 14, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Chiu's expertise for a condition
ConditionClose
      View All 20 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile